NASDAQ:MDGL - Madrigal Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$120.49 -9.45 (-7.27 %)
(As of 11/19/2018 04:00 PM ET)
Previous Close$129.94
Today's Range$120.36 - $134.75
52-Week Range$39.37 - $325.98
Volume34,502 shs
Average Volume340,897 shs
Market Capitalization$2.00 billion
P/E Ratio-47.44
Dividend YieldN/A
Beta1.56
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MDGL
Previous Symbol
CUSIP87162T20
Phone484-380-9263

Debt

Debt-to-Equity RatioN/A
Current Ratio73.69
Quick Ratio73.69

Price-To-Earnings

Trailing P/E Ratio-47.44
Forward P/E Ratio-55.02
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$13.02 per share
Price / Book9.25

Profitability

EPS (Most Recent Fiscal Year)($2.54)
Net Income$-31,150,000.00
Net MarginsN/A
Return on Equity-8.97%
Return on Assets-8.78%

Miscellaneous

Employees8
Outstanding Shares15,390,000
Market Cap$2.00 billion
OptionableOptionable

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) announced its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.03. View Madrigal Pharmaceuticals' Earnings History.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Madrigal Pharmaceuticals.

What price target have analysts set for MDGL?

10 brokerages have issued 1 year target prices for Madrigal Pharmaceuticals' shares. Their predictions range from $200.00 to $400.00. On average, they anticipate Madrigal Pharmaceuticals' stock price to reach $302.4286 in the next year. This suggests a possible upside of 144.2% from the stock's current price. View Analyst Price Targets for Madrigal Pharmaceuticals.

What is the consensus analysts' recommendation for Madrigal Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Madrigal Pharmaceuticals.

Has Madrigal Pharmaceuticals been receiving favorable news coverage?

News articles about MDGL stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of Madrigal Pharmaceuticals' key competitors?

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the folowing people:
  • Dr. Paul A. Friedman, Chairman, Pres & CEO (Age 75)
  • Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 64)
  • Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 66)

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Capital Research Global Investors (10.82%), BlackRock Inc. (3.74%), HealthCor Management L.P. (1.71%), Jennison Associates LLC (1.45%), Alliancebernstein L.P. (1.38%) and Victory Capital Management Inc. (1.26%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Marc R Schneebaum, Rebecca Taub and Richard S Levy. View Institutional Ownership Trends for Madrigal Pharmaceuticals.

Which institutional investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Perceptive Advisors LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., FMR LLC, EAM Investors LLC, AQR Capital Management LLC and Blair William & Co. IL. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last year include Bay City Capital Llc, Marc R Schneebaum and Rebecca Taub. View Insider Buying and Selling for Madrigal Pharmaceuticals.

Which institutional investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Point72 Asset Management L.P., BlackRock Inc., HealthCor Management L.P., Jennison Associates LLC, Alliancebernstein L.P., Columbus Circle Investors and University of Notre Dame DU Lac. View Insider Buying and Selling for Madrigal Pharmaceuticals.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $123.86.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $2.00 billion. The biopharmaceutical company earns $-31,150,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is http://www.madrigalpharma.com.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]


MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel